Immune check point inhibitors combination in melanoma: Worth the toxicity?

Reviews on Recent Clinical Trials

Volumn 11, Issue 2, 2016, Pages 81-86

  Orloff, Marlana ^a   Weight, Ryan ^a   Valsecchi, Matias E ^b   Sato, Takami ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Medical Oncology   (United States)

Author keywords

Anti CTLA 4; Anti PD 1; Ipilimumab; Melanoma; Nivolumab

Indexed keywords

B RAF KINASE; IPILIMUMAB; NIVOLUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CANCER IMMUNOTHERAPY; DRUG COST; DRUG RESPONSE; GENE MUTATION; HUMAN; MELANOMA; METASTATIC MELANOMA; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; CELL CYCLE CHECKPOINT; DISEASE FREE SURVIVAL; DRUG EFFECTS; MULTIMODALITY CANCER THERAPY; SKIN TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 84974678928     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/1574887111666160330120712     Document Type: Article

References (24)

1. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271(5256): 1734-6.
2. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23(4): 741-50.
3. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11(2): 155-64.
4. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8): 711-23.
5. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26): 2517-26.
6. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366(26): 2443-54.
7. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 16(3): 257-65.
8. McDermott DF, Drake CG, Sznol M, et al. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol 2015; 33(18): 2013-20.
9. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16(4): 375-84.
10. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372(1): 30-9.
11. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015; 386(9992): 444-51.
12. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369(2): 122-33.
13. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372(21): 2006-17.
14. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373(1): 23-34.
15. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372(21): 2018-28.
16. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372(4): 320-30.
17. Chustecka Z. Medscape; [cited 2015]. Available from: http: //www.medscape.com/viewarticle/845707.
18. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17(7): 2105-16.
19. Hammers H, Plimack E, Infante J, editors. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC)[abstract 4504]. Proc Am Soc Clin Oncol 2014.
20. Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther 2015; 14(4): 847-56.
21. Mahoney KM, Atkins MB. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park). 2014; 28 Suppl 3: 39-48.
22. Dronca RS, Markovic S, Kottschade LA, et al. Bim as a predictive T-cell biomarker for response to anti-PD-1 therapy in metastatic melanoma (MM). ASCO Meeting Abstracts 2015; 33(15): 9013.
23. Valsecchi ME. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373(13): 1270.
24. Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373(13): 1270-1.